Abstract

Regulatory T cells (Tregs) play a critical role in the maintenance of immune tolerance and tumor evasion. However, the relative low proportion of these cells in peripheral blood and tissues has hindered many studies. We sought to establish a rapamycin-based in vitro Treg expansion procedure in patients diagnosed with colorectal cancer and perform single-cell sequencing to explore the characteristics of Treg cells. CD25+ cells enriched from peripheral blood mononuclear cells (PBMC) of colorectal tumor patients were cultured in X-VIVO15 medium, supplemented with 5% human AB serum, L-glutamine, rapamycin, interleukin-2 (IL-2), and Dynabeads human Treg expander for 21 days to expand Tregs. Treg cells with satisfactory phenotype and function were successfully expanded from CD4+CD25+ cells in patients with colorectal cancer. The median expansion fold was 75 (range, 20–105-fold), and >90.0% of the harvest cells were CD4+CD25+CD127dim/− cells. The ratio of CD4+CD25+Foxp3+ cells exceeded 60%. Functional assays showed that iTregs significantly inhibited CD8+T cell proliferation in vitro. Single-cell sequencing showed that the transcriptome of pTreg (CD4+CD25+CD127dim/− cells isolated from PBMC of colorectal cancer patients) and iTreg (CD4+CD25+CD127dim/− cells expanded in vitro according to the above regimen) cells were interlaced. pTregs exhibited enhanced suppressive function, whereas iTregs exhibited increased proliferative capacity. TCR repertoire analysis indicated minimal overlap between pTregs and iTregs. Pseudo-time trajectory analysis of Tregs revealed that pTregs were a continuum composed of three main branches: activated/effector, resting and proliferative Tregs. In contrast, in vitro expanded iTregs were a mixture of proliferating and activated/effector cells. The expression of trafficking receptors was also different in pTregs and iTregs. Various chemokine receptors were upregulated in pTregs. Activated effector pTregs overexpressed the chemokine receptor CCR10, which was not expressed in iTregs. The chemokine CCL28 was overexpressed in colorectal cancer and associated with poor prognosis. CCR10 interacted with CCL28 to mediate the recruitment of Treg into tumors and accelerated tumor progression. Depletion of CCR10+Treg cells from tumor microenvironment (TME) could be used as an effective treatment strategy for colorectal cancer patients. Our data distinguished the transcriptomic characteristics of different subsets of Treg cells and revealed the context-dependent functions of different populations of Treg cells, which was crucial to the development of alternative therapeutic strategies for Treg cells in autoimmune disease and cancer.

Highlights

  • Regulatory T cells (Tregs) play a critical role in the regulation of self-tolerance and homeostasis [1,2,3]

  • Multiplex fluorescent IHC confirmed that CCL28 was significantly correlated with intratumoral CCR10+Treg infiltration, and high CCL28 expression and intratumoral CCR10+Treg infiltration were predictors of short progression-free survival (PFS)

  • We demonstrated successful in vitro expansion of iTreg cells in the presence of anti-CD3/anti-CD28 Dynabeads, IL-2, and rapamycin from PBMCs of patients diagnosed with colorectal cancers

Read more

Summary

Introduction

Regulatory T cells (Tregs) play a critical role in the regulation of self-tolerance and homeostasis [1,2,3]. Many studies have demonstrated that CD4(+)CD25(+)CD127dim/− was a surrogate phenotype to identify human Treg cells [6, 7]. Models of graft-vs host disease (GVHD) and autoimmune disease have evaluated the immunosuppressive properties of Treg cells [3, 8,9,10]. Treg cell expansion and modification therapies that enhance suppressive function are of significant interest for the treatment of autoimmune diseases [11]. Several studies have reported in vitro large-scale expansion of human Treg cells with a strong immunosuppressive ability for autoimmune diseases treatment [3, 12, 13]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call